Leading pharmaceutical firms beleaguered by two-way sanction

Local leading companies are faced with a burden of weakening growth potential, falling profitability and worsening financial soundness in the wake of doctors’ antipathy to them triggered by the crackdown on rebates.

Under the new guidelines, those receiving rebates and other forms of kickbacks from pharmaceutical firms may face a maximum prison term of one year or a fine of up to 30 million ...